Systematic review reveals T cell-targeted immunotherapy improves C-peptide and glycated haemoglobin in type 1 diabetes, suggesting enhanced β-cell preservation and safety.
Key Points
To evaluate the efficacy and safety of T cell-targeted immunotherapy in newly diagnosed type 1 diabetes.
Conducted a systematic review and meta-analysis of randomised controlled trials
Included trials comparing T cell-targeted immunotherapy with placebo
Primary outcome was change in C-peptide area under the curve (AUC)
T cell-targeted immunotherapy significantly increased C-peptide AUC at various time points
Reduced glycated haemoglobin and daily insulin dose
Adverse events were comparable between intervention and control groups